Apple: the next iMac would adopt a new design and an Apple Silicon processor this year

For the first time since 2012, Apple would finally renew the design of its iMac. In 2021, Apple is preparing at least three new desktop Macs. According to Bloomberg's Mark Gurman, who also released information on future MacBook Pros and iPhone 12 successors in recent days, Apple will announce an iMac and two Mac Pros in 2021. The transition to Apple Silicon processors gives a new blows to the computers of the Californian giant.     iMac: finally an edge-to-edge screen This year, the iMac could change completely. Mark Gurman indicates that the borders of his screen would be much smaller, like Pro Display XDR, the ultra high-end screen launched by Apple with the Mac Pro in 2019. The back of the computer would also abandon the curvature in favor of a completely flat frame.  This new iMac would also be equipped with an Apple Silicon processor, probably a more powerful chip than the Apple M1 chip currently present in the MacBook Air, MacBook Pro and Mac mini. The 2021 iMac is reportedly

France tightens access to chloroquine in pharmacies faced with the risk of shortage

In a press release published on Thursday, March 26 on its website, the National Agency for the Safety of Medicines and Health Products (ASNM) tells pharmacists the rules to follow regarding the delivery of hydroxychloroquine, recommended by certain infectiologists in the treatment coronavirus. An update that follows the decree framing the conditions of prescription of the drug.

France tightens access to chloroquine in pharmacies faced with the risk of shortage

Haro on hydroxychloroquine… Since Professor Didier Raoult, infectious disease specialist in Marseille, has presented it as the remedy for Covid-19, this molecule, marketed under the name of Plaquenil, has aroused an unusual craze. To the point that the Ministry of Health and the National Medicines Agency (ASNM) - which manages the famous marketing authorizations (AMM) - fear a shortage whose consequences would be dramatic for the tens of thousands of French people who treat their chronic pathologies (lupus, rheumatoid arthritis) with this drug.

To limit the danger, the Minister of Health Olivier VĂ©ran therefore issued a decree strictly governing the prescription of Plaquenil as well as another antiviral, Kaletra, also experienced in the treatment of coronavirus. Came into force on Thursday, the text provides that “the pharmaceutical specialty PLAQUENIL © and preparations based on hydroxychloroquine can only be dispensed by pharmacies as part of an initial prescription exclusively from specialists in rheumatology, internal medicine, dermatology, nephrology, neurology or pediatrics or as part of a refill from any doctor ”.

Under this text, only indoor pharmacies in healthcare establishments are now authorized to deliver Plaquenil "outside of marketing authorization", that is to say outside of its usual indications. What makes any prescription impossible for the liberal doctors, within the framework of the treatment of the coronavirus, for example.

On the other hand, the decree authorizes the prescription of Plaquenil outside MA, in the treatment of coronavirus, but it is reserved for hospital doctors: “Hydroxychloroquine and the combination lopinavir / ritonavir can be prescribed, dispensed and administered under the responsibility of a doctor to patients affected by Covid-19, in the health establishments which take charge of them, as well as, for the continuation of their treatment if their condition allows it and with the authorization of the initial prescriber, at home. ”

A few hours after the publication of the decree in the Official Journal, the National Medicines Agency has stepped up to clarify to city pharmacists the conditions for dispensing the drug. In a press release published on its website, the organization reports “difficulties in accessing city pharmacies to Plaquenil and Kaletra treatments for the chronically ill” and reminds pharmacists that to date neither Plaquenil nor Kaletra have no indication in the management of COVID-19 in the city. There is therefore no justification for their prescription in this indication ”. It remains to be seen whether this warning will be sufficient to avoid the shortage of hydroxychloroquine that threatens patients with chronic pathologies, particularly in the city of Lyon.